| Quantification of lean bodyweight S Janmahasatian, SB Duffull, S Ash, LC Ward, NM Byrne, B Green Clinical pharmacokinetics 44, 1051-1065, 2005 | 977 | 2005 |
| What is the best size descriptor to use for pharmacokinetic studies in the obese? B Green, SB Duffull British journal of clinical pharmacology 58 (2), 119-133, 2004 | 428 | 2004 |
| Dosing in obesity: a simple solution to a big problem PY Han, SB Duffull, CMJ Kirkpatrick, B Green Clinical Pharmacology & Therapeutics 82 (5), 505-508, 2007 | 289 | 2007 |
| Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development DR Mould, B Green BioDrugs 24, 23-39, 2010 | 219 | 2010 |
| The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007 SC McLeay, GA Morrish, CMJ Kirkpatrick, B Green Clinical pharmacokinetics 51, 319-330, 2012 | 160 | 2012 |
| A standard weight descriptor for dose adjustment in the obese patient SB Duffull, MJ Dooley, B Green, SG Poole, CMJ Kirkpatrick Clinical pharmacokinetics 43, 1167-1178, 2004 | 125 | 2004 |
| Development of a dosing strategy for enoxaparin in obese patients B Green, SB Duffull British journal of clinical pharmacology 56 (1), 96-103, 2003 | 123 | 2003 |
| Factors predictive of intravenous fluid administration errors in Australian surgical care wards PY Han, ID Coombes, B Green BMJ Quality & Safety 14 (3), 179-184, 2005 | 119 | 2005 |
| The effects of obesity on drug pharmacokinetics in humans GA Morrish, MP Pai, B Green Expert opinion on drug metabolism & toxicology 7 (6), 697-706, 2011 | 118 | 2011 |
| A Pharmacokinetic‐pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100 NA Lack, B Green, DC Dale, GB Calandra, H Lee, RT MacFarland, ... Clinical Pharmacology & Therapeutics 77 (5), 427-436, 2005 | 96 | 2005 |
| Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes B Green, M Greenwood, D Saltissi, J Westhuyzen, L Kluver, J Rowell, ... British journal of clinical pharmacology 59 (3), 281-290, 2005 | 92 | 2005 |
| Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug SC McLeay, P Vis, RPG Van Heeswijk, B Green Antimicrobial agents and chemotherapy 58 (9), 5315-5324, 2014 | 90 | 2014 |
| Lean body mass normalizes the effect of obesity on renal function S Janmahasatian, SB Duffull, A Chagnac, CMJ Kirkpatrick, B Green British journal of clinical pharmacology 65 (6), 964, 2008 | 87 | 2008 |
| Analysis of population pharmacokinetic data using NONMEM and WinBUGS SB Duffull, CMJ Kirkpatrick, B Green, NHG Holford Journal of Biopharmaceutical Statistics 15 (1), 53-74, 2005 | 81 | 2005 |
| Prospective evaluation of a D-optimal designed population pharmacokinetic study B Green, SB Duffull Journal of Pharmacokinetics and Pharmacodynamics 30, 145-161, 2003 | 77 | 2003 |
| Caution when lean body weight is used as a size descriptor for obese subjects B Green, S Duffull Clinical pharmacology and therapeutics 72 (6), 743-744, 2002 | 61 | 2002 |
| Population pharmacokinetics of enoxaparin during the antenatal period JP Patel, B Green, RK Patel, MS Marsh, JG Davies, R Arya Circulation 128 (13), 1462-1469, 2013 | 58 | 2013 |
| Pharmacokinetics of sapropterin in patients with phenylketonuria F Feillet, L Clarke, C Meli, M Lipson, AA Morris, P Harmatz, DR Mould, ... Clinical pharmacokinetics 47, 817-825, 2008 | 56 | 2008 |
| The impact of body weight on rivaroxaban pharmacokinetics SJ Barsam, JP Patel, LN Roberts, V Kavarthapu, RK Patel, B Green, ... Research and practice in thrombosis and haemostasis 1 (2), 180-187, 2017 | 50 | 2017 |
| Individualized compared with conventional dosing of enoxaparin MA Barras, SB Duffull, JJ Atherton, B Green Clinical Pharmacology & Therapeutics 83 (6), 882-888, 2008 | 50 | 2008 |
jignesh patelKing's College LondonBestätigte E-Mail-Adresse bei kcl.ac.uk
